selegiline has been researched along with Nerve Degeneration in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.98) | 18.7374 |
| 1990's | 21 (48.84) | 18.2507 |
| 2000's | 16 (37.21) | 29.6817 |
| 2010's | 3 (6.98) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aversa, D; Berretta, N; Cavallucci, V; Coccurello, R; Cordella, A; Cutuli, D; D'Amelio, M; De Bartolo, P; Dell'Acqua, MC; Federici, M; Giacovazzo, G; Keller, F; Krashia, P; Latagliata, EC; Marino, R; Mercuri, NB; Nobili, A; Petrosini, L; Puglisi-Allegra, S; Rizzo, FR; Sancandi, M; Viscomi, MT | 1 |
| Al-Salem, A; Hussain, AM; Kayali, NM; Khan, KM; Rao, MS; Renno, WM; Sadek, HL | 1 |
| Göltl, P; Hafenscher, F; Miklya, I; Pencz, N | 1 |
| Cohen, S; Dror, V; Eliash, S; Rehavi, M | 1 |
| Klivényi, P; Rákóczi, K; Vécsei, L | 1 |
| Carlson, EC; Ebadi, M; Sharma, SK | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Baranowski, TC; Blavo, DO; Cato, C; Doan, TN; McKinley, ET; Rubinstein, AL | 1 |
| Mohanakumar, KP; Saravanan, KS; Senthilkumar, KS; Sindhu, KM | 1 |
| Bae, BI; Cascio, MB; Dawson, TM; Dawson, VL; Hara, MR; Hester, LD; Sawa, A; Snyder, SH; Thomas, B | 1 |
| Clifford, DB; Ellis, RJ; Evans, SR; Hung, VL; Katzenstein, D; Kolson, D; Marra, CM; Millar, LL; Miller, EN; Remmel, R; Sacktor, N; Schifitto, G; Simpson, D; Singer, E; Smith, E; Valcour, V; Weihe, J; Zhang, J | 1 |
| Brew, BJ | 1 |
| Cano, J; de Pablos, RM; Herrera, AJ; Machado, A; Navarro, A; Santiago, M; Tomás-Camardiel, M; Villarán, RF | 1 |
| Mackowiak, A; Müller, T; Przuntek, H; Rieks, M | 1 |
| Chapman, H; Crook, B; Hows, ME; Medhurst, AD; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ | 1 |
| Jankovic, J; Le, W; Li, J; Pan, T; Xie, W; Youdim, MB; Zhu, W | 1 |
| Cohen, G | 1 |
| Yu, PH; Zhang, X; Zuo, DM | 1 |
| Chiueh, CC; Krishna, G; Mohanakumar, KP; Murphy, DL; Obata, T; Sternberger, LM; Wu, RM | 1 |
| Agnati, LF; Biagini, G; Frasoldati, A; Fuxe, K | 1 |
| Bhattacharya, N; Holland, D; Murray, B; Oh, C; Tatton, WG | 1 |
| Clow, A; Glover, V; Sandler, M | 1 |
| Olanow, CW | 1 |
| Finnegan, KT | 1 |
| Tatton, WG | 1 |
| Rinne, JO | 2 |
| Riederer, P; Youdim, MB | 1 |
| Bruyette, DS; Ruehl, WW; Smidberg, TL | 1 |
| Boulton, AA; Juorio, AV; Li, XM | 1 |
| Boulton, AA; Davis, BA; Yu, PH; Zhang, X; Zuo, DM | 1 |
| Chalmers-Redman, RM; Tatton, WG | 1 |
| Chalmers-Redman, RM; Ju, WY; Tatton, NA; Tatton, WG; Wadia, JS | 1 |
| Ali, SF; Freyaldenhoven, TE; Schmued, LC | 1 |
| Cano, J; Machado, A; Revuelta, M; Venero, JL | 1 |
| Boyce, S; Carlson, E; Hill, RG; Martin, JE; Rupniak, NM; Webb, JK | 1 |
| Arányi, P; Baranyi, A; Erdö, F; Takács, J | 1 |
| Klegeris, A; McGeer, PL | 1 |
| Lucius, R; Rosenstiel, P; Sievers, J | 1 |
| Boulton, AA; Davis, BA; Yu, PH | 1 |
| Deutch, AY; Deutsch, AY; Elsworth, JD; Goldstein, M; Roth, RH | 1 |
| Knoll, J | 1 |
14 review(s) available for selegiline and Nerve Degeneration
| Article | Year |
|---|---|
[The role of alpha-synuclein in Parkinson's disease].
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Endocytosis; Exocytosis; Humans; Lewy Bodies; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Prions; Protein Structure, Secondary; Selegiline | 2014 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone | 2009 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia.
Topics: Animals; Antioxidants; Basal Ganglia; Corpus Striatum; Dopamine; Free Radical Scavengers; Free Radicals; Humans; Hydroxyl Radical; Melanins; MPTP Poisoning; Nerve Degeneration; Parkinson Disease; Rats; Salicylates; Selegiline; Substantia Nigra | 1994 |
Effects of dopaminergic drugs on superoxide dismutase: implications for senescence.
Topics: Aging; Animals; Corpus Striatum; Enzyme Induction; Free Radicals; Humans; Isatin; Life Expectancy; Nerve Degeneration; Parkinson Disease; Pergolide; Rats; Selegiline; Substantia Nigra; Superoxide Dismutase | 1993 |
A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
Topics: Free Radicals; Humans; Lipid Peroxidation; Monoamine Oxidase Inhibitors; Nerve Degeneration; Parkinson Disease; Reactive Oxygen Species; Selegiline; Substantia Nigra | 1993 |
Selegiline can mediate neuronal rescue rather than neuronal protection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Isoenzymes; Mice; Mice, Inbred BALB C; Monoamine Oxidase; Motor Neurons; Nerve Degeneration; Parkinson Disease, Secondary; Selegiline; Substantia Nigra | 1993 |
Nigral degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Haplorhini; Humans; Isoenzymes; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Substantia Nigra | 1993 |
The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
Topics: Corpus Striatum; Dopamine; Humans; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroglia; Parkinson Disease; Polyamines; Reactive Oxygen Species; Selegiline; Substantia Nigra | 1993 |
Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with 1-deprenyl.
Topics: Adrenocortical Hyperfunction; Animals; Disease Models, Animal; Dogs; Dopamine; Nerve Degeneration; Pituitary Gland; Selegiline | 1995 |
Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.
Topics: Animals; Gene Expression; Humans; Monoamine Oxidase; Nerve Degeneration; Selegiline | 1996 |
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Expression Regulation; Humans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Tissue Proteins; Neurites; Neuroglia; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Protein Synthesis Inhibitors; Rats; Selegiline | 1996 |
Neuronal and astroglial monoamine oxidase: pharmacological implications of specific MAO-B inhibitors.
Topics: Animals; Astrocytes; Dopamine; Models, Neurological; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Oxidation-Reduction; Phenethylamines; Rats; Selegiline; Structure-Activity Relationship | 1992 |
Nigral degeneration in Parkinson's disease in relation to clinical features.
Topics: Corpus Striatum; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Neurologic Examination; Parkinson Disease; Selegiline; Substantia Nigra | 1991 |
2 trial(s) available for selegiline and Nerve Degeneration
| Article | Year |
|---|---|
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
Topics: Adult; Aged; AIDS Dementia Complex; Antioxidants; Brain; Cytoprotection; Female; Humans; Male; Middle Aged; Nerve Degeneration; Neuroprotective Agents; Neuropsychological Tests; Placebos; Selegiline; Treatment Failure | 2007 |
Pergolide and selegiline for Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Pergolide; Phenethylamines; Selegiline | 1989 |
27 other study(ies) available for selegiline and Nerve Degeneration
| Article | Year |
|---|---|
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Death; Dendritic Spines; Dihydroxyphenylalanine; Disease Models, Animal; Dopaminergic Neurons; Food; Hippocampus; Inflammation; Memory; Mice, Transgenic; Nerve Degeneration; Neuronal Plasticity; Nucleus Accumbens; Plaque, Amyloid; Reward; Selegiline; Ventral Tegmental Area | 2017 |
Monoamine oxidase-B inhibitor protects degenerating spinal neurons, enhances nerve regeneration and functional recovery in sciatic nerve crush injury model.
Topics: Animals; Anterior Horn Cells; Disease Models, Animal; Gene Expression Regulation; Male; Monoamine Oxidase Inhibitors; Movement; Myelin Basic Protein; Nerve Degeneration; Nerve Fibers, Myelinated; Nerve Regeneration; Pain Threshold; Phosphopyruvate Hydratase; Rats; Rats, Wistar; Recovery of Function; Sciatic Neuropathy; Selegiline; Spinal Cord; Weight-Bearing | 2018 |
Neuroprotection by rasagiline in thiamine deficient rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Indans; Kaplan-Meier Estimate; Male; Maze Learning; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Thiamine Deficiency | 2009 |
Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Cell Line, Tumor; Cell Membrane; Cytoprotection; Dose-Response Relationship, Drug; Free Radicals; Genes, Immediate-Early; Humans; Intracellular Membranes; Microscopy, Electron; Mitochondria; Nerve Degeneration; Neurites; Neuroblastoma; Neurons; Neuroprotective Agents; Oxidative Stress; Phosphatidylserines; Selegiline | 2003 |
Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Targeting; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; MPTP Poisoning; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Nomifensine; Oligodeoxyribonucleotides, Antisense; Selegiline; Species Specificity; Swimming; Tyrosine 3-Monooxygenase; Zebrafish | 2005 |
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Topics: Amphetamine; Animals; Catalase; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Electron Transport Complex I; Hydroxyl Radical; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2006 |
Neuroprotection by pharmacologic blockade of the GAPDH death cascade.
Topics: Animals; Antiparkinson Agents; Apoptosis; Cell Line; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; In Vitro Techniques; Male; Mice; MPTP Poisoning; Nerve Degeneration; Neuroprotective Agents; Nitric Oxide; Nuclear Proteins; Oxepins; Parkinson Disease; Selegiline; Ubiquitin-Protein Ligases | 2006 |
Lost in translation: again, another failed neuroprotection trial.
Topics: AIDS Dementia Complex; Antioxidants; Biomarkers; Clinical Trials as Topic; Cytoprotection; Dose-Response Relationship, Drug; Humans; Nerve Degeneration; Nerve Growth Factors; Neuroprotective Agents; Oxidative Stress; Selegiline; Treatment Failure | 2007 |
Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.
Topics: alpha-Methyltyrosine; Animals; Apoptosis; Astrocytes; Cell Respiration; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Enzyme Inhibitors; gamma-Aminobutyric Acid; Male; Microglia; Mitochondria; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neurons; Nitro Compounds; Nomifensine; Oxygen Consumption; Propionates; Rats; Rats, Wistar; Reactive Oxygen Species; Reserpine; Selegiline; Succinate Dehydrogenase; Superoxides; Synaptosomes; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cisplatin; Drug Interactions; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroblastoma; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Selegiline; Time Factors | 2008 |
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Hypoglycemic Agents; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; MPTP Poisoning; Nerve Degeneration; Neuroglia; Pioglitazone; Postural Balance; PPAR gamma; Psychomotor Performance; Selegiline; Serotonin; Substantia Nigra; Thiazolidinediones | 2008 |
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
Topics: Acetylcysteine; Animals; Dopamine; Indans; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Selegiline | 2008 |
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Topics: Animals; Brain; Catalase; Catecholamines; Dopamine; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Levodopa; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Selegiline; Superoxide Dismutase; Superoxides | 1983 |
Neuroprotection by R(-)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus coeruleus.
Topics: Adrenergic Agents; Animals; Benzylamines; Locus Coeruleus; Male; Nerve Degeneration; Neurons; Norepinephrine; Propylamines; Rats; Rats, Wistar; Selegiline | 1995 |
The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes.
Topics: Animals; Astrocytes; Cell Division; Densitometry; Fibroblast Growth Factor 2; Glial Fibrillary Acidic Protein; Image Processing, Computer-Assisted; Immunohistochemistry; Male; Neostriatum; Nerve Degeneration; Nervous System Diseases; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
(-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants.
Topics: Amphetamine; Animals; Axons; Cell Survival; Facial Nerve; Methamphetamine; Mice; Mice, Inbred A; Mice, Inbred C57BL; Mice, Neurologic Mutants; Motor Neurons; Nerve Degeneration; Selegiline; Species Specificity | 1994 |
Neurotoxins and monoamine oxidase inhibition: new aspects.
Topics: Animals; Benzylamines; Brain; Dose-Response Relationship, Drug; Isoenzymes; Male; Mice; Mice, Inbred BALB C; Monoamine Oxidase; Nerve Degeneration; Neurons; Neurotoxins; Norepinephrine; Selegiline | 1993 |
Some new mechanisms underlying the actions of (-)-deprenyl: possible relevance to neurodegeneration.
Topics: Animals; Cells, Cultured; DNA, Complementary; Gene Expression Regulation; Monoamine Oxidase Inhibitors; Nerve Degeneration; PC12 Cells; Rats; RNA, Messenger; Selegiline; Time Factors | 1995 |
Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals.
Topics: Animals; Axons; Benzylamines; Immunohistochemistry; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Endings; Neuroprotective Agents; Neurotoxins; Norepinephrine; Propylamines; Rats; Rats, Wistar; Reference Values; Selegiline; Sensitivity and Specificity | 1996 |
Systemic administration of MPTP induces thalamic neuronal degeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dizocilpine Maleate; Dopamine Agents; Male; Mice; Mice, Inbred Strains; Nerve Degeneration; Neurons; Neuroprotective Agents; Nomifensine; Selegiline; Substantia Nigra; Temperature; Thalamus | 1997 |
Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes.
Topics: Animals; Axotomy; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Female; Glial Fibrillary Acidic Protein; Immunohistochemistry; Neostriatum; Nerve Degeneration; Nerve Endings; Neuroprotective Agents; Rats; Rats, Wistar; Selegiline; Substantia Nigra; Tyrosine 3-Monooxygenase | 1997 |
Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenyl.
Topics: Animals; Disease Progression; Excitatory Amino Acid Antagonists; Female; Male; Mice; Mice, Mutant Strains; Monoamine Oxidase Inhibitors; Motor Activity; Motor Neuron Disease; Nerve Degeneration; Quinolones; Selegiline; Stereoisomerism | 1999 |
Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils.
Topics: Animals; Brain Ischemia; Cell Survival; Dose-Response Relationship, Drug; Fluorine Compounds; Gerbillinae; Hippocampus; Male; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Pyramidal Cells; Reperfusion Injury; Selegiline | 2000 |
R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Topics: Alzheimer Disease; DNA Primers; Gene Expression Regulation, Enzymologic; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Monocytes; Nerve Degeneration; Neuroblastoma; Neurons; Neurotoxins; Parkinson Disease; RNA, Messenger; Selegiline; Tumor Cells, Cultured | 2000 |
(-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo.
Topics: Animals; Axons; Brain-Derived Neurotrophic Factor; Cell Survival; Free Radicals; Ganglia, Spinal; GAP-43 Protein; Gene Expression Regulation; Genes, bcl-2; Immunohistochemistry; In Vitro Techniques; Male; Molsidomine; Monoamine Oxidase Inhibitors; Nerve Degeneration; Nerve Regeneration; Neurites; Neuroprotective Agents; Optic Nerve; Oxidative Stress; Rats; Rats, Wistar; Receptor, trkA; Receptor, trkB; Retinal Ganglion Cells; Selegiline | 2002 |
3-Acetylpyridine results in degeneration of the extrapyramidal and cerebellar motor systems: loss of the dorsolateral striatal dopamine innervation.
Topics: Animals; Cerebellum; Corpus Striatum; Dopamine; Extrapyramidal Tracts; Male; Molecular Structure; MPTP Poisoning; Nerve Degeneration; Pyridines; Rats; Rats, Inbred Strains; Selegiline | 1990 |
Extension of life span of rats by long-term (-)deprenyl treatment.
Topics: Aging; Animals; Life Expectancy; Male; Nerve Degeneration; Phenethylamines; Rats; Selegiline; Time Factors | 1988 |